Share This Article:

Socio-Economic Status and Hemoglobin Concentration of Type 2 Diabetes Mellitus Patients Attending Diabetic Clinic in Benin City, Nigeria

Abstract Full-Text HTML Download Download as PDF (Size:144KB) PP. 139-143
DOI: 10.4236/ojpathology.2013.34026    2,313 Downloads   4,152 Views  

ABSTRACT

The aim of this study is to determine the Socio Economic Status and Red Blood Cell Hemoglobin concentration alteration in type 2 Diabetes mellitus patients attending Diabetic Clinic in Benin City, Nigeria. The sample population consists of 142 subjects, 71 of patients were known in Type 2 Diabetes mellitus already on drugs and were confirmed to be Diabetic using Glucose oxidase method while the other 71 subjects were age matched apparently healthy control subject on routine check up, they were confirmed to be non Diabetic using the Glucose oxidase method. Hemoglobin concentrations were done using the Cyanmethemoglobin method. Those under the low income Socio-Economic status had the highest incidence of type 2 Diabetes mellitus (49%) of the Diabetic population, closely followed by the middle income Socio-Economic status (35%) of the Diabetic populations. The Mean ± S.D of Hemoglobin concentration of control subjects against Mean ± S.D of Hemoglobin concentration of the various Socio-Economic status of Males and Females type 2 Diabetes mellitus patient show a statistically significant decrease (P < 0.05). Type 2 Diabetes mellitus is associated with Anemia irrespective of Socio-Economic status. Prevention of the Global Diabetes epidemic must include regular national surveys, introduction of Diabetes health education in schools, emphasis on balance diet, regular exercise and abstention from tobacco smoking.

 

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

A. Ehiaghe, J. Ehiaghe, O. Ifeanyichukwu, I. Isioma, J. Ize-Iyamu and L. Ize-Iyamu, "Socio-Economic Status and Hemoglobin Concentration of Type 2 Diabetes Mellitus Patients Attending Diabetic Clinic in Benin City, Nigeria," Open Journal of Pathology, Vol. 3 No. 4, 2013, pp. 139-143. doi: 10.4236/ojpathology.2013.34026.

References

[1] D. Hansen, P. L. Dendale, M. Beelen, A. Jonkers, A. Mullens and L. Coruy, “Plasma Adipokine and Inflammatory Marker Concentrations Are Altered in Obese, as Opposed to Non-Obese, Type 2 Diabetes Patients,” European Journal of Applied Physiology, Vol. 109, No. 3, 2010, pp. 397-404.
[2] International Diabetes Federation, “Diabetes Atlas,” 5th Edition, 2011.
[3] World Health Organization, “Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report on the Diagnosis and Classification of Diabetes Mellitus,” Diabetes Care, Vol. 20, 1997, pp. 1183-1197.
[4] World Health Organization, “Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow up Report on the Diagnosis of Diabetes Mellitus,” Diabetes Care, Vol. 26, No. 11, 2003, pp. 3160-3167. http://dx.doi.org/10.2337/diacare.26.11.3160
[5] S. Chinenye, D. I. Uchenna, C. N. Unachukwu, A. O. Ogbera and A. C. Ojule, “The Pattern of Diabetes Mellitus in Rivers State, Nigeria,” Nigerian Endocrine Practice, Vol. 2, 2008, pp. 87-93.
[6] A. A. Motala, “Diabetes Trends in Africa,” Diabetes/ Metabolism Research and Reviews, Vol. 18, Suppl. 3, 2002, pp. 514-520.
[7] S. Vigan, “Type 2 Diabetes,” Annals of Internal Medicine, Vol. 152, No. 5, 2010, p. 31.
[8] S. H. Sayolah, M. Miret, J. Sung, C. Varas, D. Gause and F. L. Brancati, “Post Challenge Hyperglycemia and Mortality in a National Sample of U.S Adults,” Diabetes Care, Vol. 24, No. 8, 2001, pp. 1397-1402.
[9] A. Osibogun, “The Medicine for Poverty: An Argument for Health and Development. The Ninth Sir Samuel Manuwa Lecture,” 36th Annual General and Scientific Meeting, West African College of Physicians (Nigeria Chapter), Uyo, 2012.
[10] “Health Report,” WHO Regional Office, WHO, Brazzaville, 2006.
[11] O. O. Ainkugbe, “Non Communicable Disease in Nigeria: National Survey (Final Report) on Hypertension, Coronary Heart Disease, Diabetes Mellitus Hemoglobinopatheis, GGPD Deficiency and Anemia. National Expert Committee on Non-Communicable Disease,” Federal Ministry of Health and Social Services, Lagos, 1997.
[12] A. A. Motala, T. Esterhrizen and E. Gouwa, “Diabetes and Other Disorders of Glycaemia in a South African Community: Prevalence and Associated Risk Factor,” Diabetes Cares, Vol. 31, No. 9, 2008, pp. 1783-1788.
[13] K. Rossing, P. K. Christensen, P. Hovind, L. Tarnow, P. Rossing and H. H. Parving, “Progression of Nephropathy in Type 2 Diabetic Patients,” Kidney International, Vol. 66, No. 4, 2004, pp. 1596-1605. http://dx.doi.org/10.1111/j.1523-1755.2004.00925.x
[14] World Health Organization, “Worldwide Prevalence of Anemia,” WHO, Geneva, 2008.
[15] L. Naing, T. Winn and B. N. Rusli, “Practical Issues in Calculating the Sample Size for Prevalence Studies,” Archives of Orofacial Sciences, Vol. 1, 2006, pp. 9-14.
[16] D. Barham and P. Trinder, “An Improved Colour Reagent for the Determination of Blood Glucose by the Oxidase System,” Analyst, Vol. 97, 1972, pp. 142-145. http://dx.doi.org/10.1039/an9729700142
[17] J. Dacis and D. Lewis, “Practical Hematology,” 8th Edition, Churchill Livingstone, London, 2006, pp. 27-30.
[18] K. G. Alberti, P. Zimmet and I. Shaw, “International Diabetes Federation: A Consensus on Type 2 Diabetes Prevention,” Diabetes Medicals, Vol. 24, No. 5, 2007, pp. 451-468. http://dx.doi.org/10.1111/j.1464-5491.2007.02157.x
[19] Diabetes Care and Research in Europe, “The Saint Vincent. Declaration,” Diabetic Medicals, Vol. 7, 1990, p. 360. http://dx.doi.org/10.1111/j.1464-5491.1990.tb01405.x
[20] World Health Organization, “Prevalence of Diabetes Mellitus. Report of a WHO Study Group,” WHO, No 844. 1994.
[21] K. Rossing, P. K. Christensen, P. Hovind, et al., “Progression of Nephropathy in Type 2 Diabetic,” Kidney International, Vol. 66, 2004, pp. 1596-1605. http://dx.doi.org/10.1111/j.1523-1755.2004.00925.x
[22] P. K. Ranil, R. Raman and S. R. Rachepalli, “Anemia and Diabetic Retinopathy in Type 2 Diabetes Mellitus,” Journal of Association of Physicians India, Vol. 58, 2010, pp. 91-94.
[23] J. P. New, I. Aung and P. G. Baker, “The High Prevalence of Unrecognized Anemia in Patients with Diabetes and Chronic Kidney Disease: A Population Based Study,” Diabetes Medicine, Vol. 25, No. 5, 2008, pp. 564-569. http://dx.doi.org/10.1111/j.1464-5491.2008.02424.x
[24] D. R. Bosman, C. A. Osborn, J. T. Marsden, I. C. Macdougall, W. N. Gardner and P. Watkins, “Erythropoietin Response to Hypoxia in Patients with Diabetic Autonomic Neutropathy and Non Diabetic Chronic Renal Failure,” Diabetic Medical, Vol. 19, No. 1, 2002, pp. 65-69. http://dx.doi.org/10.1046/j.1464-5491.2002.00634.x
[25] G. A. Kaysen, “The Microinflammatory State in Uremia: Causes and Potential Consequences,” Journal of the American Society of Nephrology, Vol. 12, 2001, pp. 1549-1557.
[26] M. Goicoechea, J. Martin, P. De Sequera, J. A. Qunoga, A. Ortiz, V. Carreno and C. Caramelo, “Role of Cytokines in the Response to Erythropoietin in Hemo Dialysis Patients,” Kidney International, Vol. 54, No. 4, 1998, pp. 1337-1343. http://dx.doi.org/10.1046/j.1523-1755.1998.00084.x
[27] E. O. Zanjani, P. B. McGlave, S. F. Davies, M. Banisadre, M. E. Caplan and G. A. Sarosi, “In Vitro Suppression of Erythropoiesis by Bone Marrow Adherent Cells from Some Patients with Fungal Infection,” British Journal of Hematology, Vol. 50, No. 3, 1998, pp. 479-490.
[28] D. R. Bosman, A. S. Winkler, J. T. Marsden, I. C. Macdousall and P. J. Watkins, “Anemia with Erythropoietin Deficiency Occurs Early in Diabetic Nephropathy,” Diabetes Care, Vol. 24, No. 3, 2001, pp. 495-499. http://dx.doi.org/10.2337/diacare.24.3.495
[29] J. C. Kathrine, D. W. Joh, G. R. Stephen, S. Hilary, R. O. David, W. Debbie, C. Ivor and O. P. Aled, “Anemia and Diabetes in the Absence of Nephtropathy,” Diabetes Care, Vol. 28, No. 5, 2005, pp. 1118-1123.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.